No­var­tis stakes an­oth­er PhI­II win for Cosen­tyx, goes deep­er in­to pe­di­atric mar­kets

Just hours af­ter the FDA cleared No­var­tis’ Cosen­tyx for its first pe­di­atric in­di­ca­tion, the com­pa­ny is fol­low­ing up with more pos­i­tive da­ta on an­oth­er: ju­ve­nile …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER